Efficacy and Safety of GLP-1 Receptor Agonists on Combined Cardiovascular and Renal Outcomes in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis.
Diabetes Obes MetabJun 23, 2026 (epub)
Rashpinder Kaur, Avtar Singh
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and network meta-analysis evaluated the efficacy and safety of GLP-1 receptor agonists in patients with chronic kidney disease (CKD). Among 13 randomized controlled trials involving 31,846 CKD patients, GLP-1 RAs significantly reduced major adverse cardiovascular events (MACE) by 16% (HR 0.84) and the composite kidney endpoint by 21% (HR 0.79).
Key findings
- GLP-1 RAs reduced MACE by 16% (HR 0.84, 95% CI 0.79-0.89).
- The composite kidney endpoint was reduced by 21% (HR 0.79, 95% CI 0.73-0.86).
- Kidney failure risk decreased by 28% (HR 0.72).
- Semaglutide ranked highest in the network meta-analysis with a SUCRA of 78.4%.
Why it matters
The findings highlight the potential of GLP-1 receptor agonists to provide significant cardiovascular and renal protection in patients with CKD, which is crucial given the high morbidity associated with these conditions.